The discovery was made possible through computer simulations with an unprecedented level of detail. The results are available online to support the development of new, targeted drugs for a wide range of diseases.

Research centers from thirteen countries collaborated on the study, which has been published in Nature Communications.

Some types of tumours secrete two molecules, TGF-β and Activin A, which supress the capacity of NK cells to attack them.

A team of researchers from the Hospital del Mar Research Institute, the Universitat Autònoma de Barcelona and the Pompeu Fabra University has developed a new tool that allows modifying these NK cells to make them immune to the tumour's defense mechanism.

Researchers have found that the absence of this antibody leads to an overgrowth of gut microbiota, triggering an excessive and sustained immune system response, which ultimately becomes exhausted and fails to respond effectively to vaccines.

The study, published in Science Advances, opens the door to exploring the possibility of early immunoglobulin therapy administration to prevent this process and reduce the risk of potentially dangerous infections, even in at-risk individuals without a diagnosed immunodeficiency.

For the first time, it has been confirmed that, contrary to previous beliefs, individual neurons represent the concepts we learn, regardless of the context in which we encounter them.

This allows humans, unlike other animals, to establish higher and more abstract relationships, which lays the foundation of human intelligence.

The study has significant relevance, impacting the management of bladder cancer patients. Machine learning tools enabled the identification of key variables for the success of immunotherapy treatment.

This innovative methodology has allowed researchers to pinpoint which tumor subtypes respond best to immunotherapy.

These results reinforce the start of the phase 2 clinical trial, through an international multicenter study with people with Down syndrome, focused on the dose necessary to achieve the treatment goal.

Additionally, having a high-quality breakfast with a balanced intake of proteins, high-value fats, fiber, calcium, and iron is associated with a 1.5% smaller waist circumference, 4% lower triglycerides, and 3% higher HDL cholesterol.

The study tracked nearly 400 participants of the PREDIMED-Plus study over three years, which analyzes the effects of the Mediterranean diet on participants' health.

This dual mechanism of action has demonstrated safety and achieved complete and durable antitumor responses in patient-derived models of HER2+ p95HER2-expressing solid tumors.

Published in Nature Communications, results of this VHIO-led study have provided the rationale for the application of a phase 1 first-in-human clinical trial, currently in the approval process, to assess this novel therapeutic strategy in patients with HER2-driven solid tumors.

This study is mainly supported by the Asociación Española Contra el Cáncer (AECC) through AUSONIA and has also received funding from the Breast Cancer Research Foundation (BCRF), Fundación BBVA through the Comprehensive Program of Cancer Immunotherapy and Immunology (CAIMI), which is one of VHIO's Institutional Programs focused on developing new advanced therapies.